Gowling WLG advised Eisai Co., Ltd. on the deal. Morgan Lewis advised Advanz Pharma.
Eisai Co., Ltd. agreed to divest its rights for the antiepileptic agent Zonegran® (zonisamide) in Europe and other regions to Advanz Pharma.
Under the agreement, Eisai will transfer to Advanz Pharma the rights to Zonegran® in a number of European countries, the Middle East, Russia, and Australia. Eisai will continue to act as the distributor in Russia and Australia, through its local affiliated companies, for an agreed transition period. In addition, Eisai and Advanz Pharma have agreed to enter into a supply agreement under which Eisai’s UK affiliate, Eisai Manufacturing Limited, will serve as Advanz Pharma’s supplier of Zonegran for the transferred territory for an agreed transition period.
Eisai is a global research and development-based pharmaceutical company, headquartered in Japan. Established in 1941, it has grown to employ more than 10,000 employees worldwide and reports an annual revenue of ¥645.9 billion. Gowling WLG has worked with Eisai for more than 13 years.
Morgan, Lewis & Bockius UK LLP advised Advanz Pharma on this transaction.
Gowling WLG life sciences partner Luke Kempton (Picture) led on the deal, supported by partner Patrick Duxbury and legal director Mathilda Davidson. Partner Neil Hendron advised on corporate issues, partner Bernardine Adkins on anti-trust issues, with employment advice provided by principal associate Hannah Swindle. They worked closely with Eisai’s Simon Thomas, General Counsel EMEA, Oliver Arnott, Legal Counsel EMEA and James Hiscock, Senior Legal Counsel EMEA.
Morgan Lewis partner Nick Moore and associate Humphrey Thomas represented Advanz Pharma.
Involved fees earner: Bernardine Adkins – Gowling WLG; Mathilda Davidson – Gowling WLG; Patrick Duxbury – Gowling WLG; Neil Hendron – Gowling WLG; Luke Kempton – Gowling WLG; Hannah Swindle – Gowling WLG; Nicholas Moore – Morgan Lewis & Bockius; Humphrey Thomas – Morgan Lewis & Bockius;